Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Freezing out tumors: new hope for rare desmoid disease

NCT ID NCT02476305

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a freezing technique called cryoablation on 50 adults with desmoid tumors that had grown despite medical treatment. The goal was to stop tumor growth and ease symptoms without surgery. Researchers used MRI to guide the freezing and check results one year later.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cryoablation (freezing therapy using cryoprobes)
What this could lead to
If successful, cryoablation could provide a non-surgical way to control desmoid tumors, reduce pain, and improve quality of life for patients who have not responded to other treatments.
What could go wrong
This is a small, early-phase study (50 participants) with no control group. The procedure may not work for all tumor locations, and there is a risk of incomplete destruction or recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

May 2015

Finished

Nov 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Extra-abdominal desmoid tumor (confirmed by prior biopsy) * 18 years of age or older * Tumor deemed accessible for cryoablation procedure by the operator in the investigator center * At least one measurable lesion (RECIST v1.1) using MRI (gadolinium injection mandatory) * 90 % of destruction of the tumor achievable in one procedure of cryoablation with a possible second cryoablation procedure (if a complete treatment must be achieved). * Progressive disease under standard treatment (after at least two lines of adequate medical therapy, including tamoxifen, non-steroid anti-inflamatory or chemotherapy), with presence of functional symptoms and/or pain The definition of progressing tumors also involves patients with RECIST stable disease, but with persistent functional disability or tumor-induced pain not controlled by adequate pain medication including narcotics. * Unresectable tumor or tumor amenable only to mutilating surgery, deemed inappropriate, and discussed in multidisciplinary meeting (RCP) * ECOG performance status 0-2 * Biological and hematological parameters: * neutrophils 1,5.109/L * platelet count 100.109/L * No significant hemostatic abnormalities * Subject affiliated to social security * Signed informed consent Exclusion Criteria: * Any contra-indication for the procedure as stated by the radiologist in terms of tumor size, proximity to neural/vascular structures making the procedure at unacceptable risk * Impaired hemostasis, that may interfere with the conduct of the cryoablation * Concurrent participation in other experimental studies that could affect endpoints of this study * Contraindication to any form of sedation * Contraindication to MRI or gadolinium injection (proven allergy, subject with impaired renal function (defined by a creatinine clearance below 30 ml/min by MDRD formula)) * Psychiatric disorders and adults under guardianship * Pregnancy or breastfeeding * Patients under judicial protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Desmoid tumors are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service d'Imagerie Interventionnelle

    Strasbourg, Alsace, 67091, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.